Background Despite the concerns about a potential increased risk of skin cancer and lymphoma with the use of topical tacrolimus and pimecrolimus, no population-based studies have given an overview of the use of these drugs in Europe.
Introduction
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a wide range of clinical presentations and is one of the most common skin disorders in children [2, 3] . For many years, the most common treatment for AD was topical corticosteroids. In 2002, new topical treatment options in the form of tacrolimus ointment and pimecrolimus cream were approved for the treatment of AD. Topical tacrolimus and topical pimecrolimus are the only topical calcineurin inhibitors (TCIs) in Europe. In 2002, topical tacrolimus was approved for short or intermittent long-term treatment of moderate to severe AD in Europe. Two concentrations of topical tacrolimus are available; 0.1% for use in patients over 16 years of age, and 0.03% for use in children over 2 years of age. The indication for topical tacrolimus was extended in 2009 to maintenance treatment of AD. Topical pimecrolimus in a concentration of 1% was approved in 2002 for the treatment of mild-tomoderate AD in patients over 2 years of age. Both drugs are approved for second-line treatment only, for patients in whom other treatments have been ineffective or are contraindicated.
At the time of approval of both products, the long-term safety in humans was not fully established, though animal studies indicated a potential risk of skin cancer of both products [4, 5] . In March 2005, the US Food and Administration (FDA) issued a public health advisory followed by a label change in January 2006, including a boxed warning [6, 7] . Similarly, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended a change in the product information and a Direct Healthcare Professional Communication (DHPC) letter was sent by the marketing authorization holders of topical tacrolimus and topical pimecrolimus to healthcare professionals with important risk minimization measures [8] .
To date, no population-based studies have given an overview of the use of topical tacrolimus and topical pimecrolimus for the treatment of AD in Europe. Therefore, the purpose of this population-based study is to give an overview of the use of topical tacrolimus and topical pimecrolimus across population-based health databases in four European countries between 2002 and 2011.
Methods

Study Design and Setting
In this multicentre database cohort study, data were retrieved from population-based health databases in four European countries: the PHARMO Database Network (PHARMO) in the Netherlands, the Danish National Prescription Registry, the Swedish Prescribed Drug Registry, and the Clinical Practice Research Datalink (CPRD) in the UK.
The PHARMO Database Network is a population-based, patient-centric data tracking system that includes detailed information on prescribed healthcare products dispensed by the outpatient pharmacies [9, 10] . The PHARMO Database Network covers a catchment area representing more than 4 million residents. In Denmark and Sweden, each national healthcare system provides universal coverage to all residents. The Danish National Prescription Registry started in 1995 and contains data on prescribed and dispensed medicine for all 5.7 million residents in Denmark [11] . The Swedish Prescribed Drug Registry started in July 2005 and contains data on prescribed and dispensed medicine for all 9.2 million residents in Sweden [12] . The CPRD contains data collated by General Practitioners (GPs) for over 5 million active patients representing over 8% of the general population and includes detailed information on prescriptions issued in primary care [13] . Drug dispensings and prescriptions are coded according to the WHO Anatomical Therapeutic Chemical (ATC) Classification System in PHARMO (Netherlands), Denmark and Sweden, and according to Gemscript codes in CPRD (UK).
Hereafter, issued prescriptions recorded in CPRD are referred to as dispensings.
Participants
The study population in each country comprised children 
Treatment Characteristics
In the study period, the mean total number of dispensings per patient of topical tacrolimus and topical pimecrolimus was calculated. The number of users of topical tacrolimus and topical pimecrolimus by year was also determined. For each country, the proportion of total topical tacrolimus and topical pimecrolimus users was tabulated by year. The proportion of users in each year was calculated by dividing the number of topical tacrolimus users or topical pimecrolimus users in a specific year by the total number of topical tacrolimus users or topical pimecrolimus users throughout the study period. The strength (0.1 or 0.03%) of the first topical tacrolimus dispensing was determined. The first switch between topical tacrolimus and topical pimecrolimus (or vice versa) that occurred between the first dispensing in the study period and the end of that patient's follow-up was reported.
Statistical Analyses
The data extraction and analysis for each database were based on a common protocol. Treatment characteristics were reported as percentages for categorical variables, and mean with standard deviation (SD) (if available) for continuous variables. All analyses were conducted within two age cohorts (B18 years and [18 years) and within each data source.
Results
In total, there were 32,052 children and 104,902 adults treated with topical tacrolimus, and 32,125 children and 58,280 adults treated with topical pimecrolimus. In Denmark the most commonly used TCI for both children and adults was topical pimecrolimus, whereas topical tacrolimus was the predominant TCI choice for both age groups in the other countries. Of the study population, the most users of topical pimecrolimus were from Denmark (74% of all children and 69% of all adults) ( Table 1 ). Denmark and Sweden contributed together 71% of all children and 70% of all adult users of topical tacrolimus. The mean number of topical tacrolimus dispensings per child varied between 2.0 (Sweden) and 4.6 (UK). For adults, this ranged from 2.2 (Denmark and Sweden) to 3.6 (UK). The mean number of topical pimecrolimus dispensings ranged from 2.0 (Netherlands) to 2.4 (UK) among children and from 2.0 (Sweden) to 2.9 (UK) among adults.
In Sweden, the prescription registry started in July 2005 and users from January 2006 and onwards were included. Information in the first 4 years after launch of topical tacrolimus and topical pimecrolimus was therefore not available on an individual level. However, based on aggregate Swedish sales data on prescription of the drugs during the entire period of marketing (data not shown), a sharp decline in sales of topical tacrolimus was observed between 2004 and 2006 and a minor decline of topical pimecrolimus between 2004 and 2005. Across the other data sources, the number of topical tacrolimus users increased steadily after launch among both children and adults ( Table 2) . For topical pimecrolimus, there was a peak in the number of users in the first 2 years after its first availability, especially among children ( where the decrease in the number of children using topical pimecrolimus continued through 2011. In Denmark, the majority of children received topical tacrolimus with a strength of 0.1% (61%) (Fig. 2) whereas a strength of 0.03% was predominantly dispensed to children (56-69%) in all other countries. Adults were more often dispensed a topical tacrolimus strength of 0.1% in all countries (66-88%). In the UK, a small number of patients (67 children and 260 adults) had dispensings for both topical tacrolimus strengths (0.03 and 0.1%) on the same day; these patients contributed to both groups in Fig. 2 .
Overall, the number of users switching from initially prescribed topical pimecrolimus to topical tacrolimus was higher compared with users starting with topical tacrolimus and switching to topical pimecrolimus ( Table 3 ). The number of children switching from topical tacrolimus to topical pimecrolimus during follow-up ranged from 1% in Sweden to 7% in Denmark. The number of children switching from topical pimecrolimus to topical tacrolimus ranged from 10% in the Netherlands and the UK to 13% in Sweden. Similar results were found for adults (Table 3) .
Discussion
This is the first study evaluating the use of topical tacrolimus and topical pimecrolimus across four European countries in both children and adults. The results of this population-based multicentre database cohort study provide an overview of the use of topical tacrolimus and topical pimecrolimus in four European countries.
In this study, there was a difference seen in the type of TCI prescribed to children and adults across the four countries; in Denmark most children and adults were prescribed topical pimecrolimus, whereas in the other countries the preference was for topical tacrolimus. The use of topical tacrolimus and topical pimecrolimus increased in the first years after approval. This increase was steeper for topical pimecrolimus. There was a decrease seen in topical tacrolimus and topical pimecrolimus users in the Netherlands and Denmark from 2004 and in the UK from 2005. The number of users of topical tacrolimus increased again The pattern of use of topical tacrolimus and topical pimecrolimus may have been the result of the increased awareness of the concerns about a potential increased risk of skin cancer and lymphoma with the use of topical tacrolimus and topical pimecrolimus [14, 15] , but there is no additional evidence to support this explanation. However, regulatory measures were undertaken, including a public health advisory in March 2005 and a label change in January 2006 [6, 7] . In the European Union as well as the USA the labelling of topical tacrolimus and topical pimecrolimus was updated by adding a warning about cautious use of topical tacrolimus and topical pimecrolimus in order to reduce the potential risk of skin cancer and lymphoma. In addition, a DHPC letter was sent by the marketing authorization holders of topical tacrolimus and topical pimecrolimus to healthcare professionals with important risk minimization measures, in accordance with the CHMP [8] . Following the extension of the indication of topical tacrolimus to maintanance treatment of AD in the EU in 2009, a further reminder about minimization of cancer risk was sent to all healthcare providers [16] . However, this reminder seems to have less impact on the number of users of both topical tacrolimus and topical pimecrolimus.
The change in the pattern of use following these regulatory actions and responses from the the medical community was also seen based on worldwide sales data of topical tacrolimus and topical pimecrolimus published by Siegfried et al. [17] . Here, worldwide sales data of topical tacrolimus and topical pimecrolimus showed a decrease in sales within a year of the public health advisory and updated labelling. Comparable with the results in our study, the wordwide sales of topical pimecrolimus continued to decline, while the sales of topical tacrolimus slightly increased.
Topical tacrolimus and topical pimecrolimus are not indicated for children younger than 2 years of age. However, in our study, we know that off-label use of topical tacrolimus in children younger than 2 years of age did occur and ranged from 0.3% in the Netherlands to 3.7% in Fig. 1 Proportion of total users in each country over the years among a children using topical tacrolimus, b adults using topical tacrolimus, c children using topical pimecrolimus and d adults using topical pimecrolimus, stratified by country. *In Sweden, data from July 2005 were available, but only users from 2006 were included Denmark and for topical pimecrolimus from 1.4% in the Netherlands to 11% in Denmark (data not shown). A previous study also showed that off-label use of topical tacrolimus and topical pimecrolimus in children younger than 2 years of age decreased substantially in association with regulatory actions [18] .
In this large population-based study in European databases, the data extraction and analysis for each health database were based on a common protocol that permitted combining the results across databases. However, some differences between the databases exist. In the UK, data on topical tacrolimus and topical pimecrolimus were obtained from GP prescriptions, which do not contain information on whether the prescription was actually filled or not. For Denmark and Sweden, information on topical tacrolimus and topical pimecrolimus dispensings was obtained from national registers covering the entire Danish and Swedish population. In Sweden, full data on the number of users was available from 2006 onwards and the pattern of use on an invididual level could only be determined after that period. Data from the Netherlands and the UK were available for a subset of the population, but have been shown to be representative of the general population of these countries [13, [19] [20] [21] . 
Conclusion
In conclusion, the use of topical tacrolimus and topical pimecrolimus grew rapidly after regulatory approval. Safety warnings issued by regulatory agencies about a potential risk of cancer may have contributed to the temporary reduction in users of topical tacrolimus and persistent reduction in users of topical pimecrolimus in all countries, especially in children.
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